دورية أكاديمية
أعرض في EDS

Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital.

التفاصيل البيبلوغرافية
العنوان: Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital.
المؤلفون: Moussa M; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Elshorbagy MS; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Emarah A; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Gaber R; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Moussa OM; Ophthalmology Department, Faculty of Medicine, Kafr-Elsheikh University, Kafr-Elsheikh, Egypt., El-Bradey M; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Alagorie AR; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt., Sorour OA; Ophthalmology Department, Faculty of Medicine, Tanta University, Elgeish street, Tanta, 31111, Egypt. Osama.soror@med.tanta.edu.eg.
المصدر: International ophthalmology [Int Ophthalmol] 2021 Apr; Vol. 41 (4), pp. 1437-1443. Date of Electronic Publication: 2021 Jan 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Country of Publication: Netherlands NLM ID: 7904294 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2630 (Electronic) Linking ISSN: 01655701 NLM ISO Abbreviation: Int Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer
Original Publication: The Hague, Junk.
مواضيع طبية MeSH: COVID-19* , Diabetic Retinopathy*/drug therapy , Intravitreal Injections* , Macular Edema*/drug therapy, Angiogenesis Inhibitors/*administration & dosage , Bevacizumab/*administration & dosage, Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/therapeutic use ; Clinical Audit ; Hospitals ; Humans ; Pandemics ; Treatment Outcome ; Visual Acuity
مستخلص: Background: The aims of this study were to provide real-life data about the effect of COVID-19 pandemic on the practice of anti-VEGF injections and to evaluate the safety of the modifications in the injection protocol imposed during the ongoing pandemic on the anatomical and functional outcome of patients.
Methods: All patients attending Tanta University hospital for receiving intravitreal anti-VEGF injections were screened. Patients who were previously deferred according to a modified protocol implemented in the hospital in response to the pandemic or who demonstrated deviation from it were included for further analysis.
Results: During the audit period, 83 patients attending for anti-VEGF injections were screened, of whom 40 met the abovementioned criteria and were included for analysis. In the deferred subgroup (11 eyes), predeferral mean values of logMAR best corrected visual acuity (BCVA) and central retinal subfield thickness (CST) were 1 ± 0.23 and 444.57 ± 200.1 µm, respectively. There was no significant change when the patients returned for their deferred injections, with the mean BCVA and CST values being 0.8 ± 0.22 and 413.71 ± 237.7 µm, respectively (p = 0.27 and p = 0.12). Moreover, 29 patients encountered a disturbed injection schedule, particularly skipping their injection appointments due to infection fear as found in 18 patients.
Conclusion: The COVID-19 pandemic has imposed pressing challenges in maintaining essential health care while ensuring the prevention of spread of infection. Although the modified injection protocol confirmed to be safe for patients, the pandemic caused deflection from the optimum practice in the form of successive skipping of appointments and delays in the processing of patient injection schedules.
References: Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW (2020) Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefe’s Arch Clinic and Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 258:1049–1055. (PMID: 10.1007/s00417-020-04641-8)
Agarwal D, Kumar A (2020) Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era- Initial experiences. Indian J Ophthalmol 68:1216–1218. (PMID: 10.4103/ijo.IJO_1391_20)
Romano MR, Montericcio A, Montalbano C, Raimondi R, Allegrini D, Ricciardelli G, Angi M, Pagano L, Romano V (2020) Facing COVID-19 in Ophthalmology department. Curr Eye Res 45:653–658. (PMID: 10.1080/02713683.2020.1752737)
Shmueli O, Chowers I, Levy J (2020) Current safety preferences for intravitreal injection during COVID-19 pandemic. Eye 34:1165–1167. (PMID: 10.1038/s41433-020-0925-x)
Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, Lanzetta P, Li X, Lovestam-Adrian M, Navarro R et al (2020) Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe’s Arch Clinic Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 258:1149–1156. (PMID: 10.1007/s00417-020-04703-x)
Sengupta S, Honavar SG, Sachdev MS, Sharma N, Kumar A, Ram J, Shetty R, Rao GS, Ramasamy K, Khanna R et al (2020) All India ophthalmological society - Indian journal of ophthalmology consensus statement on preferred practices during the COVID-19 pandemic. Indian J Ophthalmol 68:711–724. (PMID: 10.4103/ijo.IJO_1853_20)
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M et al (2019) Effect of initial management With Aflibercept vs. Laser Photocoagulation vs. observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA 321:1880–1894. (PMID: 10.1001/jama.2019.5790)
Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, Hageman G, Guymer RH (2012) Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 153:678–686. (PMID: 10.1016/j.ajo.2011.09.013)
Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, Investigators F (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with Ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126:723–734. (PMID: 10.1016/j.ophtha.2018.11.025)
Lanzetta P, Loewenstein A (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefe’s Arch Clinic Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 255:1259–1273. (PMID: 10.1007/s00417-017-3647-4)
فهرسة مساهمة: Keywords: Anti-VEGF; COVID-19; Choroidal neovascularization; Diabetic macular edema; Injection protocol; Pandemic
المشرفين على المادة: 0 (Angiogenesis Inhibitors)
2S9ZZM9Q9V (Bevacizumab)
تواريخ الأحداث: Date Created: 20210121 Date Completed: 20210426 Latest Revision: 20210426
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC7818066
DOI: 10.1007/s10792-021-01719-y
PMID: 33475906
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-2630
DOI:10.1007/s10792-021-01719-y